Attached is a press
release issued earlier this morning by GlaxoSmithKline,
announcing that topline results have been received from seven of the
eight Harmony Phase 3 studies investigating the use of albiglutide in
type 2 diabetes.
Albiglutide was created by HGS using its proprietary albumin-fusion
technology, and was licensed to GSK in 2004. HGS is entitled to fees and
milestone payments that could amount to as much as $183 million -
including $33.0 million received to date - in addition to single-digit
net royalties on worldwide sales if albiglutide is commercialized.
All inquiries regarding the albiglutide Phase 3 data announced today
should be directed to the contacts provided by GSK.
Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes